...
首页> 外文期刊>Kidney Research and Clinical Practice >Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra
【24h】

Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra

机译:Anakinra治疗后改善Erdheim-Chester病相关的肾衰竭

获取原文
           

摘要

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by infiltrates of lipid-laden CD68^+/CD1a^- histiocytes, affecting heart, lungs, central nervous system, and bones. Kidney and adjacent structures can also be affected, leading to renal failure in about 30% of cases. The diagnosis is challenging, and treatment is generally based on administration of interferon-alpha (IFN@a), but preliminary results also showed the therapeutic efficacy of anakinra, an antagonist of the receptor of interleukin-1 (IL-1). We report the case of an elderly patient with ECD and severe involvement of the heart and kidneys who was successfully treated with anakinra.
机译:Erdheim-Chester病(ECD)是一种罕见的非朗格汉斯细胞组织细胞增生症,其特征是充满脂质的CD68 ^ + / CD1a ^-组织细胞浸润,影响心脏,肺,中枢神经系统和骨骼。肾脏和邻近结构也会受到影响,导致约30%的病例导致肾衰竭。诊断具有挑战性,治疗通常基于干扰素-α(IFNα)的给药,但初步结果还显示了白介素-1(IL-1)受体拮抗剂anakinra的治疗效果。我们报道了一例老年患者的ECD和严重的心脏和肾脏受累,成功地使用了anakinra治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号